Research Article

NETWORK-BASED ANALYSIS OF PROTAC COMPOUNDS TARGETING CDK4/6 IN BREAST CANCER: IDENTIFICATION OF GENE INTERACTIONS AND THERAPEUTIC INSIGHTS

Volume: 8 Number: 1 April 29, 2026
EN TR

NETWORK-BASED ANALYSIS OF PROTAC COMPOUNDS TARGETING CDK4/6 IN BREAST CANCER: IDENTIFICATION OF GENE INTERACTIONS AND THERAPEUTIC INSIGHTS

Abstract

Cancer is a major disease characterized by rapid and uncontrolled cell growth and proliferation, affecting a large population worldwide. A significant portion of cancer research today involves network analysis. In this study, the gene targets of 8-Cyclopentyl-2-(4-piperazin-1-ylanilino) pteridin-7-one (CPPP-7-one) and the PROTAC CDK4/6 degrader (PROTAC-CDK4/6i) were identified, and their shared targets with breast cancer-related genes were examined. Additionally, protein-protein interactions (PPI) involving the gene targets of these compounds were mapped. The analysis revealed that CDK4 is a common gene target between breast cancer and the CPPP-7-one compound. In contrast, GRM2, the sole gene target of the PROTAC CDK4/6 degrader, did not overlap with any breast cancer-related genes. These findings suggest that CPPP-7-one may play a significant role in cyclin and cyclin-dependent kinase activities, particularly in regulating cell cycle checkpoints, and therefore warrants further investigation. Furthermore, the isolated nature of PROTAC CDK4/6i's target from core cell cycle proteins indicates that it may influence distinct intracellular mechanisms.

Keywords

References

  1. Bolton EE, Chen J, Kim S, Han L, He S, Shi W, Simonyan V, Sun Y, Thiessen PA, Wang J, Yu B, Zhang J, Bryant SH. PubChem3D: A new resource for scientists. J Cheminform. 2011 Sep 20; 3(1):32. [PubMed PMID: 21933373] https://doi.org/10.1186/1758-2946-3-32
  2. Bondeson DP, et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat Chem Biol. 2015. Burslem GM, Crews CM. Proteolysis-targeting chimeras as therapeutics and tools for biological discovery. Cell. 2020.
  3. Daina, A., & Zoete, V. (2024). Testing the predictive power of reverse screening to infer drug targets, with the help of machine learning. Communications chemistry, 7(1), 105. https://doi.org/10.1038/s42004-024-01179-2 Das J, Gayvert KM, Bunea F, et al. ENCAPP: elastic-net-based prognosis prediction and biomarker discovery for human cancers. BMC Genomics 2015; 16:263.
  4. Gfeller, D., Michielin, O., & Zoete, V. (2013). Shaping the interaction landscape of bioactive molecules. Bioinformatics, 29(23), 3073-3079.
  5. Hu, Y., Gao, J., Wang, M., & Li, M. (2021). Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer. Cancer management and research, 13, 5223–5237. https://doi.org/10.2147/CMAR.S310649
  6. Joung, J. G., Kim, D., Lee, S. Y., Kang, H. J., & Kim, J. H. (2014). Integrated analysis of microRNA-target interactions with clinical outcomes for cancers. BMC medical genomics, 7 Suppl 1(Suppl 1), S10. https://doi.org/10.1186/1755-8794-7-S1-S10
  7. Kim, S., Chen, J., Cheng, T., Gindulyte, A., He, J., He, S., Li, Q., Shoemaker, B. A., Thiessen, P. A., Yu, B., Zaslavsky, L., Zhang, J., & Bolton, E. E. (2025). PubChem 2025 update. Nucleic Acids Res., 53(D1), D1516–D1525. https://doi.org/10.1093/nar/gkae1059
  8. Li, R., Liu, M., Yang, Z., Li, J., Gao, Y., & Tan, R. (2022). Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future. Molecules (Basel, Switzerland), 27(24), 8828. https://doi.org/10.3390/molecules27248828

Details

Primary Language

English

Subjects

Biological Network Analysis

Journal Section

Research Article

Publication Date

April 29, 2026

Submission Date

July 21, 2025

Acceptance Date

January 23, 2026

Published in Issue

Year 2026 Volume: 8 Number: 1

APA
Tamtürk, E., & Yalcin, S. (2026). NETWORK-BASED ANALYSIS OF PROTAC COMPOUNDS TARGETING CDK4/6 IN BREAST CANCER: IDENTIFICATION OF GENE INTERACTIONS AND THERAPEUTIC INSIGHTS. Sabuncuoglu Serefeddin Health Sciences, 8(1), 1-6. https://doi.org/10.55895/sshs.1747653
AMA
1.Tamtürk E, Yalcin S. NETWORK-BASED ANALYSIS OF PROTAC COMPOUNDS TARGETING CDK4/6 IN BREAST CANCER: IDENTIFICATION OF GENE INTERACTIONS AND THERAPEUTIC INSIGHTS. SSHS. 2026;8(1):1-6. doi:10.55895/sshs.1747653
Chicago
Tamtürk, Erkut, and Serap Yalcin. 2026. “NETWORK-BASED ANALYSIS OF PROTAC COMPOUNDS TARGETING CDK4 6 IN BREAST CANCER: IDENTIFICATION OF GENE INTERACTIONS AND THERAPEUTIC INSIGHTS”. Sabuncuoglu Serefeddin Health Sciences 8 (1): 1-6. https://doi.org/10.55895/sshs.1747653.
EndNote
Tamtürk E, Yalcin S (April 1, 2026) NETWORK-BASED ANALYSIS OF PROTAC COMPOUNDS TARGETING CDK4/6 IN BREAST CANCER: IDENTIFICATION OF GENE INTERACTIONS AND THERAPEUTIC INSIGHTS. Sabuncuoglu Serefeddin Health Sciences 8 1 1–6.
IEEE
[1]E. Tamtürk and S. Yalcin, “NETWORK-BASED ANALYSIS OF PROTAC COMPOUNDS TARGETING CDK4/6 IN BREAST CANCER: IDENTIFICATION OF GENE INTERACTIONS AND THERAPEUTIC INSIGHTS”, SSHS, vol. 8, no. 1, pp. 1–6, Apr. 2026, doi: 10.55895/sshs.1747653.
ISNAD
Tamtürk, Erkut - Yalcin, Serap. “NETWORK-BASED ANALYSIS OF PROTAC COMPOUNDS TARGETING CDK4 6 IN BREAST CANCER: IDENTIFICATION OF GENE INTERACTIONS AND THERAPEUTIC INSIGHTS”. Sabuncuoglu Serefeddin Health Sciences 8/1 (April 1, 2026): 1-6. https://doi.org/10.55895/sshs.1747653.
JAMA
1.Tamtürk E, Yalcin S. NETWORK-BASED ANALYSIS OF PROTAC COMPOUNDS TARGETING CDK4/6 IN BREAST CANCER: IDENTIFICATION OF GENE INTERACTIONS AND THERAPEUTIC INSIGHTS. SSHS. 2026;8:1–6.
MLA
Tamtürk, Erkut, and Serap Yalcin. “NETWORK-BASED ANALYSIS OF PROTAC COMPOUNDS TARGETING CDK4 6 IN BREAST CANCER: IDENTIFICATION OF GENE INTERACTIONS AND THERAPEUTIC INSIGHTS”. Sabuncuoglu Serefeddin Health Sciences, vol. 8, no. 1, Apr. 2026, pp. 1-6, doi:10.55895/sshs.1747653.
Vancouver
1.Erkut Tamtürk, Serap Yalcin. NETWORK-BASED ANALYSIS OF PROTAC COMPOUNDS TARGETING CDK4/6 IN BREAST CANCER: IDENTIFICATION OF GENE INTERACTIONS AND THERAPEUTIC INSIGHTS. SSHS. 2026 Apr. 1;8(1):1-6. doi:10.55895/sshs.1747653

               34329                            
34328
 

This journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.